Dr. Matthew Edmund Boyd Dixon, MD

Dr. Dixon practices at Rush University Medical Center in Chicago, Illinois, part of Rush System for Health.

Dr. Dixon's NPI, 1083842009, was assigned on June 29, 2009. Dr. Dixon graduated from St. George's University School of Medicine in 2009. Dr. Dixon holds Illinois license 036159866.

Dr. Dixon's primary practice is Rush University Medical Center, at 1653 West Congress Parkway, Chicago, IL 60612 in Cook County. The practice phone is (312) 942-5000.

Dr. Dixon's primary practice is Rush University Medical Center in Chicago, Illinois, part of Rush System for Health. Dr. Dixon is also affiliated with St. Mary Medical Center. The medical group on file is Rush University Internists. Dmand AI also links Dr. Dixon to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dixon practices, 4 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Dixon's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Dixon is board certified in complex general surgical oncology by the American Board of Surgery. Dmand AI has Dr. Dixon's licenses on file in 3 states: Illinois, Indiana and Pennsylvania.

CMS data shows 162 Medicare services from Dr. Dixon across 4 procedure codes in 2024, for 106 Medicare patients. Medicare paid $20,431 for them.

CMS counts 106 Medicare patients who saw Dr. Dixon in 2024. The largest group is 65 to 74, with 57 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dixon's median patient age at 70, with 50% women.

In 2024, Dr. Dixon wrote 64 Medicare Part D claims for 25 patients. 72% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $10,449 in total drug cost. In 2023, CMS named 19 claims across 1 drug.

Dr. Dixon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dixon as offering telehealth.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 42 papers to Dr. Dixon, published from 2012 to 2024. 2021 was the busiest year, with 9. The most frequent topics are Stomach Neoplasms, Adenocarcinoma and Pancreatic Neoplasms. Dr. Dixon has published most often in Ann Surg Oncol. Dr. Dixon's most frequent co-authors are June S. Peng, MD, Niraj Jaysukh Gusani, MD and Madeline Beatriz Torres, MD.

CMS Open Payments shows 12 general payments to Dr. Dixon from 4 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $222.

Dr. Dixon graduated from St. George's University School of Medicine in 2009. Dr. Dixon is a member of ACS.

Dr. Dixon is in network with 19 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.